FDA Expands Mounjaro Approval to Include Cardiovascular Risk Reduction in Type 2 Diabetes

The U.S. Food and Drug Administration has expanded the approved use of Mounjaro (tirzepatide) to include reducing the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for cardiovascular disease.

The FDA decision, announced August 28, 2026, adds an important cardiovascular indication to a medication already used to help manage blood glucose in people with type 2 diabetes.

Why Cardiovascular Risk Matters in Type 2 Diabetes

Diabetes and cardiovascular health are closely connected. People with type 2 diabetes have an increased risk of heart disease and stroke, which is why diabetes care extends beyond monitoring blood glucose or A1C.

Blood pressure, cholesterol, weight, kidney function, family history, smoking history, physical activity and other metabolic factors can all contribute to an individual’s cardiovascular risk.

For physicians, this means that treating type 2 diabetes often involves considering both glucose control and the prevention of longer-term complications, including cardiovascular disease.

What the Study Found

The expanded FDA approval was based on results from SURPASS-CVOT, a large cardiovascular outcomes trial involving more than 13,000 participants in 30 countries.

Researchers compared tirzepatide with dulaglutide (Trulicity), a GLP-1 receptor agonist that already has an established cardiovascular benefit. Participants were followed for more than four years.

The study evaluated three major cardiovascular outcomes: cardiovascular death, nonfatal heart attack and nonfatal stroke.

Tirzepatide was found to be noninferior to dulaglutide for the combined risk of these events. The tirzepatide group experienced an 8% lower rate of the combined cardiovascular endpoint compared with the dulaglutide group, with a hazard ratio of 0.92. However, the confidence interval crossed 1.0, so this finding should not be interpreted as demonstrating that tirzepatide is superior to dulaglutide for cardiovascular protection.

The results instead provide evidence that tirzepatide offers cardiovascular risk reduction in addition to its established effects on blood glucose and weight.

Looking Beyond Blood Sugar

The FDA’s decision reflects a broader shift in how physicians approach type 2 diabetes.

Managing diabetes is not simply about reaching a particular A1C. It is also important to understand a patient’s overall cardiovascular and metabolic health and identify risk factors before they lead to serious complications.

This is particularly relevant because cardiovascular disease can develop without obvious symptoms. Regular assessment of blood pressure, cholesterol and other lipids, kidney function, blood glucose and additional cardiovascular risk factors can help provide a more complete picture of health.

What This Means for Patients

The expanded indication does not mean tirzepatide is appropriate for every person with type 2 diabetes. Medication decisions should be individualized based on a patient's medical history, cardiovascular risk, other medications, treatment goals, potential side effects and other health considerations.

The most common adverse effects associated with tirzepatide continue to be gastrointestinal, including nausea, diarrhea, decreased appetite, vomiting, constipation and abdominal discomfort. There are also additional warnings, precautions and contraindications that should be considered before treatment.

For patients who are already taking Mounjaro, the new FDA indication provides additional information about its potential role in managing cardiovascular risk. Patients should not change their dose or other medications based on the new approval without discussing it with their physician.

At Williams + Weiss, we encourage patients with type 2 diabetes to view cardiovascular health as part of the larger picture of preventive care. Understanding individual risk and addressing it early can help guide decisions about medications, nutrition, physical activity and other strategies for maintaining long-term health.

Source: U.S. Food and Drug Administration approval and results from the SURPASS-CVOT cardiovascular outcomes trial, announced August 28, 2026.